Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Average Recommendation of “Hold” from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given an average rating of “Hold” by the eight ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $5.25.

Separately, Wells Fargo & Company boosted their price target on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research note on Monday, December 15th.

Insider Transactions at Maravai LifeSciences

In other Maravai LifeSciences news, Director Gregory T. Lucier purchased 48,528 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was purchased at an average cost of $3.67 per share, with a total value of $178,097.76. Following the completion of the acquisition, the director directly owned 155,123 shares of the company’s stock, valued at $569,301.41. This trade represents a 45.53% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.11% of the stock is owned by company insiders.

Institutional Investors Weigh In On Maravai LifeSciences

Several large investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its position in Maravai LifeSciences by 12.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock worth $112,000 after purchasing an additional 5,160 shares during the last quarter. Performa Ltd US LLC grew its holdings in shares of Maravai LifeSciences by 33.3% during the second quarter. Performa Ltd US LLC now owns 22,990 shares of the company’s stock worth $55,000 after buying an additional 5,740 shares during the last quarter. Epacria Capital Partners LLC increased its position in Maravai LifeSciences by 6.8% in the 3rd quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock valued at $287,000 after acquiring an additional 6,384 shares during the period. Ethic Inc. increased its position in Maravai LifeSciences by 62.8% in the 3rd quarter. Ethic Inc. now owns 16,951 shares of the company’s stock valued at $49,000 after acquiring an additional 6,540 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Maravai LifeSciences by 121.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock valued at $43,000 after acquiring an additional 9,870 shares during the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Stock Down 2.0%

Maravai LifeSciences stock opened at $2.96 on Friday. The company has a market capitalization of $756.90 million, a PE ratio of -3.52 and a beta of 0.39. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29. Maravai LifeSciences has a fifty-two week low of $1.66 and a fifty-two week high of $4.40. The firm has a 50 day moving average price of $3.52 and a 200 day moving average price of $3.14.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.